Sasja F. Mulder

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Bernard Escudier, Jan Roigas, Silke Gillessen et al. · Journal of Clinical Oncology · 2009 · 208 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Marye J. Boers‐Sonderen, Tim J. van Oostenbrugge, Otto C. Boerman et al. · European Urology · 2015 · 104 citations

Medicine, Oncology, Pharmacology +15

Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

Sasja F. Mulder, Dirk Bertens, Ingrid M.E. Desar et al. · BMC Cancer · 2014 · 75 citations · Full text

Medicine, Oncology, Psychology +16

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

Nienke A. G. Lankheet, Ingrid M.E. Desar, Sasja F. Mulder et al. · British Journal of Clinical Pharmacology · 2017 · 72 citations · Full text

Pharmacy, Oncology, Pharmacology +14